

Charles M Rudin

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/97800/publications.pdf](https://exaly.com/author-pdf/97800/publications.pdf)

Version: 2025-02-01

346
papers

57,028
citations

1183

105
h-index

778

235
g-index

778
all docs

778
docs citations

778
times ranked

63679
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Chromothripsis-Mediated Small Cell Lung Carcinoma. <i>Cancer Discovery</i> , 2025, 15, 83-104. | 26.4 | 2 |
| 2 | <i>TERT</i> Expression and Clinical Outcome in Pulmonary Carcinoids. <i>Journal of Clinical Oncology</i> , 2025, 43, 214-225. | 17.1 | 0 |
| 3 | Reply to P. de Boissieu et al. <i>Journal of Clinical Oncology</i> , 2025, 43, 355-356. | 17.1 | 0 |
| 4 | Alveolar Differentiation Drives Resistance to <i>KRAS</i> Inhibition in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2024, 14, 308-325. | 26.4 | 11 |
| 5 | SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2024, 42, 324-335. | 17.1 | 29 |
| 6 | Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation. <i>Cancer Immunology Research</i> , 2024, 12, 308-321. | 3.7 | 3 |
| 7 | Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer. <i>Science Advances</i> , 2024, 10, . | 11.3 | 15 |
| 8 | Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions. <i>Science Advances</i> , 2024, 10, . | 11.3 | 8 |
| 9 | RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2024, 42, 2317-2326. | 17.1 | 10 |
| 10 | Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. <i>JCO Precision Oncology</i> , 2024, , . | 2.1 | 2 |
| 11 | A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2024, 30, 3697-3703. | 6.4 | 2 |
| 12 | Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. <i>Npj Precision Oncology</i> , 2024, 8, . | 6.9 | 4 |
| 13 | Intratumoral <i>Escherichia</i> Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2024, 42, 3339-3349. | 17.1 | 0 |
| 14 | CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, . | 26.3 | 4 |
| 15 | Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2024, , . | 2.1 | 0 |
| 16 | Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> Amplification. <i>JCO Precision Oncology</i> , 2024, , . | 2.1 | 0 |
| 17 | ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. <i>Science Advances</i> , 2024, 10, . | 11.3 | 2 |
| 18 | CTLA4 blockade abrogates <i>KEAP1</i> / <i>STK11</i> -related resistance to PD-(L)1 inhibitors. <i>Nature</i> , 2024, 635, 462-471. | 40.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. <i>Immunity</i> , 2023, 56, 93-106.e6. | 22.7 | 47 |
| 20 | Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Cocksackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. , 2023, 11, e005007. | | 18 |
| 21 | IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. <i>Journal of Clinical Investigation</i> , 2023, 133, . | 9.1 | 52 |
| 22 | Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2023, 41, 2877-2880. | 17.1 | 7 |
| 23 | Breathing room – focusing on the “other” lung cancer. <i>Nature Cancer</i> , 2023, , . | 13.9 | 0 |
| 24 | De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways. <i>Clinical Cancer Research</i> , 2023, 29, 3526-3540. | 6.4 | 8 |
| 25 | Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. <i>Nature Immunology</i> , 2023, 24, 1020-1035. | 13.1 | 21 |
| 26 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 4408-4418. | 6.4 | 10 |
| 27 | Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. , 2023, 11, e006994. | | 3 |
| 28 | Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. <i>Oncologist</i> , 2023, 28, 1007-e1107. | 3.6 | 7 |
| 29 | Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. <i>Science Translational Medicine</i> , 2023, 15, . | 13.1 | 18 |
| 30 | Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. <i>Cancer Discovery</i> , 2022, 12, 562-585. | 26.4 | 55 |
| 31 | Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100256. | 1.0 | 5 |
| 32 | Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. <i>Cancer Research</i> , 2022, 82, 472-483. | 0.6 | 29 |
| 33 | Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1401-1407. | 6.6 | 28 |
| 34 | Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. <i>Clinical Cancer Research</i> , 2022, 28, 1391-1401. | 6.4 | 30 |
| 35 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11. | 35.1 | 310 |
| 36 | Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597. | 18.1 | 102 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 37 | Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. <i>Nature Communications</i> , 2022, 13, . | 14.1 | 28 |
| 38 | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459. | 0.9 | 17 |
| 39 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e325-e329. | 2.8 | 6 |
| 40 | Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma. <i>Clinical Cancer Research</i> , 2022, 28, 2938-2952. | 6.4 | 11 |
| 41 | WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. <i>Cell Reports</i> , 2022, 39, 110814. | 6.4 | 63 |
| 42 | POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1109-1121. | 1.1 | 41 |
| 43 | Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers. <i>Cancer Research</i> , 2022, 82, 6238-6238. | 0.6 | 1 |
| 44 | Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. <i>JCO Precision Oncology</i> , 2022, , . | 2.1 | 8 |
| 45 | Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1014-1031. | 1.1 | 58 |
| 46 | Delta-like ligand 3â€“targeted radioimmunotherapy for neuroendocrine prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, . | 7.7 | 31 |
| 47 | Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3797-3803. | 6.4 | 25 |
| 48 | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139. | 26.4 | 20 |
| 49 | Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. <i>Clinical Cancer Research</i> , 2022, 28, 4702-4713. | 6.4 | 44 |
| 50 | Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. <i>Nature Communications</i> , 2022, 13, . | 14.1 | 18 |
| 51 | cfDNA methylome profiling for detection and subtyping of small cell lung cancers. <i>Nature Cancer</i> , 2022, 3, 1260-1270. | 13.9 | 64 |
| 52 | Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. <i>Nature Reviews Clinical Oncology</i> , 2022, 20, 16-32. | 25.3 | 19 |
| 53 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 2353-2363. | 25.6 | 74 |
| 54 | Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240. | 6.7 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 532-541. | 6.4 | 28 |
| 56 | Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1997-2010. | 6.4 | 20 |
| 57 | <i>MET</i> Exon 14 altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806. | 6.4 | 44 |
| 58 | A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 240-244. | 26.4 | 10 |
| 59 | TMEM41B Is a Pan-flavivirus Host Factor. <i>Cell</i> , 2021, 184, 133-148.e20. | 35.1 | 129 |
| 60 | Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2209-2215. | 6.4 | 75 |
| 61 | <i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612. | 6.4 | 24 |
| 62 | Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927. | 6.4 | 45 |
| 63 | Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. <i>Bioconjugate Chemistry</i> , 2021, 32, 1255-1262. | 3.9 | 11 |
| 64 | N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection. <i>Viruses</i> , 2021, 13, 769. | 3.3 | 6 |
| 65 | ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 503-514. | 13.9 | 88 |
| 66 | Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. <i>Genes and Development</i> , 2021, 35, 870-887. | 4.8 | 9 |
| 67 | Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047. | 26.4 | 95 |
| 68 | An optimized NGS sample preparation protocol for <i>in vitro</i> CRISPR screens. <i>STAR Protocols</i> , 2021, 2, 100390. | 1.1 | 2 |
| 69 | Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, . | 14.1 | 89 |
| 70 | Abstract LB186: MAPK pathway activation represents a therapeutic vulnerability in ASCL1-driven SCLC. , 2021, , . | | 0 |
| 71 | Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9. | 33.4 | 113 |
| 72 | Quantitative <i>In Vivo</i> Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma. <i>Cancer Research</i> , 2021, 81, 4570-4580. | 0.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 73 | A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763. | 26.4 | 320 |
| 74 | MYC Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 3214-3229. | 26.4 | 26 |
| 75 | Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73. | 2.1 | 18 |
| 76 | Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. <i>Cancer Cell</i> , 2021, 39, 1245-1261.e6. | 33.4 | 83 |
| 77 | Small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, . | 24.7 | 801 |
| 78 | Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. <i>Cancer Cell</i> , 2021, 39, 1479-1496.e18. | 33.4 | 204 |
| 79 | Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, . | 24.7 | 42 |
| 80 | A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry. <i>Viruses</i> , 2021, 13, 2113. | 3.3 | 11 |
| 81 | MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. <i>iScience</i> , 2021, 24, 103224. | 3.8 | 16 |
| 82 | Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2021, 126, 889-898. | 5.7 | 14 |
| 83 | SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247. | 1.1 | 201 |
| 84 | Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 144, 101-104. | 0.9 | 21 |
| 85 | SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835. | 1.1 | 293 |
| 86 | Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. <i>Cell Reports</i> , 2020, 33, 108444. | 6.4 | 144 |
| 87 | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. <i>Frontiers in Oncology</i> , 2020, 10, . | 2.7 | 331 |
| 88 | Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , 2020, 38, 229-246.e13. | 33.4 | 215 |
| 89 | Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2020, 26, 5424-5437. | 6.4 | 19 |
| 90 | Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1522-1534. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 91 | The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708. | 6.4 | 153 |
| 92 | Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18. | 35.1 | 789 |
| 93 | Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12957-12977. | 6.9 | 60 |
| 94 | Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1871-1879. | 1.1 | 26 |
| 95 | Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2175-2185. | 1.7 | 8 |
| 96 | CNS Metastases in Patients With MET Exon 14 Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, , 871-876. | 2.1 | 18 |
| 97 | Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, . | 14.1 | 31 |
| 98 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379. | 17.1 | 487 |
| 99 | Lineage plasticity in cancer: a shared pathway of therapeutic resistance. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 360-371. | 25.3 | 309 |
| 100 | Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. <i>Clinical Cancer Research</i> , 2020, 26, 147-158. | 6.4 | 68 |
| 101 | Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. <i>Nature Cancer</i> , 2020, 1, 359-369. | 13.9 | 25 |
| 102 | Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , 2020, 579, 284-290. | 40.1 | 244 |
| 103 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540. | 1.1 | 123 |
| 104 | Regenerative lineages and immune-mediated pruning in lung cancer metastasis. <i>Nature Medicine</i> , 2020, 26, 259-269. | 25.6 | 266 |
| 105 | Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020, 25, 140-149. | 3.6 | 44 |
| 106 | A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1796-1802. | 6.4 | 10 |
| 107 | Clinical outcomes, local regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211. | 0.9 | 44 |
| 108 | Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858. | 6.4 | 86 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 109 | HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687. | 26.4 | 180 |
| 110 | SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. <i>Lung Cancer</i> , 2020, 145, 126-131. | 2.1 | 18 |
| 111 | Targeted Therapies and Biomarkers in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, . | 2.7 | 71 |
| 112 | Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i> -Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069. | 6.4 | 263 |
| 113 | Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793. | 1.1 | 250 |
| 114 | Lessons learned from routine, targeted assessment of liquid biopsies for <i>EGFR</i> T790M resistance mutation in patients with <i>EGFR</i> mutant lung cancers. <i>Acta Oncologica</i> , 2019, 58, 1634-1639. | 1.9 | 11 |
| 115 | Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126. | 6.4 | 41 |
| 116 | Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1122-1124. | 1.1 | 0 |
| 117 | The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019, 25, 6916-6924. | 6.4 | 235 |
| 118 | Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1583-1593. | 1.1 | 66 |
| 119 | Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966. | 6.4 | 221 |
| 120 | Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. <i>Nature Cell Biology</i> , 2019, 21, 1403-1412. | 10.5 | 289 |
| 121 | Frequency and outcomes of brain metastases in patients with <i>HER2</i> mutant lung cancers. <i>Cancer</i> , 2019, 125, 4380-4387. | 4.4 | 61 |
| 122 | Positron-Emission Tomographic Imaging of a Fluorine 18 Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1743-1752. | 1.1 | 16 |
| 123 | Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35. | 3.3 | 67 |
| 124 | Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. <i>Science Signaling</i> , 2019, 12, . | 5.5 | 141 |
| 125 | ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019, 10, . | 14.1 | 164 |
| 126 | Immunophenotype and Response to Immunotherapy of <i>RET</i> -Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2019, , 1-8. | 2.1 | 81 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 127 | <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. <i>JCO Precision Oncology</i> , 2019, , 1-8. | 2.1 | 39 |
| 128 | Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2019, 14, 802-815. | 1.1 | 77 |
| 129 | High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. <i>Clinical Cancer Research</i> , 2019, 25, 4712-4722. | 6.4 | 318 |
| 130 | Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. <i>Modern Pathology</i> , 2019, 32, 1106-1122. | 5.0 | 60 |
| 131 | Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019, 19, 289-297. | 24.2 | 760 |
| 132 | Epigenetic targeting of DNA repair in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22429-22431. | 7.7 | 5 |
| 133 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937. | 25.6 | 497 |
| 134 | Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2019, , 1-9. | 2.1 | 27 |
| 135 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206. | 16.3 | 2,692 |
| 136 | Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14 mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1248-1260. | 6.4 | 97 |
| 137 | A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583. | 5.1 | 102 |
| 138 | Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 38, 419-432. | 2.6 | 62 |
| 139 | Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630. | 9.1 | 103 |
| 140 | Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695. | 26.4 | 158 |
| 141 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4. | 33.4 | 801 |
| 142 | Target engagement imaging of PARP inhibitors in small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, . | 14.1 | 72 |
| 143 | Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340. | 6.4 | 339 |
| 144 | Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973. | 6.4 | 93 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 145 | Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i> -Mutant Lung Cancers. <i>JCO Precision Oncology</i> , 2018, , 1-12. | 2.1 | 71 |
| 146 | Ado-Trastuzumab Emtansine for Patients With <i>HER2</i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537. | 17.1 | 416 |
| 147 | Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641. | 17.1 | 1,087 |
| 148 | Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394. | 17.1 | 301 |
| 149 | <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835. | 26.4 | 1,145 |
| 150 | Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. <i>Clinical Cancer Research</i> , 2018, 24, 5143-5152. | 6.4 | 65 |
| 151 | Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018, 6, 1093-1099. | 3.7 | 269 |
| 152 | Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. <i>Oncogene</i> , 2018, 38, 656-670. | 6.6 | 142 |
| 153 | Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , 2017, 31, 286-299. | 33.4 | 385 |
| 154 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>NF2</i> Loss-Driven Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1693-1704. | 1.7 | 34 |
| 155 | Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 3931-3941. | 0.6 | 84 |
| 156 | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2017, 18, 42-51. | 21.9 | 428 |
| 157 | Unravelling the biology of SCLC: implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 549-561. | 25.3 | 332 |
| 158 | Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209. | 1.1 | 41 |
| 159 | MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S406-S407. | 1.1 | 12 |
| 160 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609. | 26.4 | 499 |
| 161 | Histone Code Aberrancies in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 599-601. | 1.1 | 2 |
| 162 | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. <i>Nature Medicine</i> , 2017, 23, 1362-1368. | 25.6 | 480 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 163 | Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 548-554. | 1.4 | 37 |
| 164 | A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1764-1776. | 2.9 | 67 |
| 165 | Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945. | 2.9 | 36 |
| 166 | Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. <i>Radiotherapy and Oncology</i> , 2017, 125, 130-135. | 0.9 | 37 |
| 167 | A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-III A resectable NSCLC. <i>EJNMMI Research</i> , 2017, 7, . | 2.7 | 16 |
| 168 | Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2. | 2.8 | 29 |
| 169 | PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 523-535. | 6.4 | 265 |
| 170 | Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. <i>Radiology</i> , 2017, 282, 251-258. | 9.6 | 25 |
| 171 | Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717. | 17.1 | 864 |
| 172 | Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. <i>Journal of Oncology</i> , 2017, 2017, 1-5. | 1.7 | 18 |
| 173 | Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. <i>Journal of Clinical Investigation</i> , 2017, 127, 2957-2967. | 9.1 | 62 |
| 174 | Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. <i>Annals of Translational Medicine</i> , 2017, 5, 479-479. | 1.8 | 11 |
| 175 | Small-cell lung cancer in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2017, 6, S67-S70. | 2.1 | 4 |
| 176 | Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. <i>Modern Pathology</i> , 2017, 31, 111-121. | 5.0 | 49 |
| 177 | Abstract CT115: Phase 1b KEYNOTE 200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients. <i>Cancer Research</i> , 2017, 77, CT115-CT115. | 0.6 | 12 |
| 178 | Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome. , 2017, , . | | 0 |
| 179 | CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 2610-2620. | 9.1 | 338 |
| 180 | Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. <i>PLoS ONE</i> , 2016, 11, e0160587. | 2.5 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 181 | Missing the mark in <i>FGFR1</i> -amplified squamous cell cancer of the lung. <i>Cancer</i> , 2016, 122, 2938-2940. | 4.4 | 7 |
| 182 | Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). <i>Cancer</i> , 2016, 122, 2371-2378. | 4.4 | 58 |
| 183 | P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. <i>Science Translational Medicine</i> , 2016, 8, . | 13.1 | 173 |
| 184 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660. | 21.9 | 378 |
| 185 | The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27. | 2.1 | 11 |
| 186 | A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 23-30. | 2.1 | 58 |
| 187 | A combinatorial strategy for treating KRAS-mutant lung cancer. <i>Nature</i> , 2016, 534, 647-651. | 40.1 | 322 |
| 188 | Medians and Milestones in Describing the Path to Cancer Cures. <i>JAMA Oncology</i> , 2016, 2, 167. | 13.6 | 38 |
| 189 | Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129. | 2.8 | 114 |
| 190 | Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Oncology Practice</i> , 2016, 12, 83-86. | 3.5 | 30 |
| 191 | Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2897-2907. | 6.4 | 49 |
| 192 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474. | 1.1 | 144 |
| 193 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629. | 6.4 | 343 |
| 194 | Shining light on novel targets and therapies. <i>Nature Reviews Clinical Oncology</i> , 2016, 14, 75-76. | 25.3 | 51 |
| 195 | Abstract 3756: PARP inhibitor sensitivity in small cell lung cancer cell lines and patient-derived xenografts correlates with SLFN11 expression but not with structural homologous recombination deficiency. , 2016, , . | | 0 |
| 196 | Abstract 4356: Identification of the anthrax toxin receptor (ANTXR1) as the high affinity cellular receptor for Seneca Valley Virus (SV). , 2016, , . | | 0 |
| 197 | Abstract 4187: Loss of SLFN11 or gain of TWIST1 promote chemotherapy resistance in small cell lung cancer. , 2016, , . | | 1 |
| 198 | A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. <i>Cell Reports</i> , 2015, 13, 2159-2173. | 6.4 | 54 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 199 | Phase I trial of Seneca Valley Virus (NTXâ€010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 743-750. | 1.5 | 65 |
| 200 | Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 56-70. | 1.7 | 26 |
| 201 | Hedgehog Signaling Pathway Is Active in GBM with GLI1 mRNA Expression Showing a Single Continuous Distribution Rather than Discrete High/Low Clusters. <i>PLoS ONE</i> , 2015, 10, e0116390. | 2.5 | 23 |
| 202 | Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. <i>PLoS ONE</i> , 2015, 10, e0129103. | 2.5 | 7 |
| 203 | RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015, 6, . | 14.1 | 488 |
| 204 | Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1021-1026.e8. | 1.3 | 177 |
| 205 | Small cell lung cancer: <i>Where do we go from here?</i> . <i>Cancer</i> , 2015, 121, 664-672. | 4.4 | 465 |
| 206 | The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015, 47, 250-256. | 16.3 | 431 |
| 207 | Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. <i>Neuro-Oncology</i> , 2015, 17, 545-554. | 0.9 | 72 |
| 208 | Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 3-13. | 1.7 | 72 |
| 209 | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. <i>Oral Oncology</i> , 2015, 51, 383-388. | 2.1 | 70 |
| 210 | Genomic Analysis of Smoothed Inhibitor Resistance in Basal Cell Carcinoma. <i>Cancer Cell</i> , 2015, 27, 327-341. | 33.4 | 305 |
| 211 | Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping. <i>Cancer Discovery</i> , 2015, 5, 842-849. | 26.4 | 502 |
| 212 | Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. <i>Clinical Cancer Research</i> , 2015, 21, 2244-2255. | 6.4 | 178 |
| 213 | Molecularly Targeted Therapies in Nonâ€Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63. | 1.1 | 113 |
| 214 | Nivolumab versus Docetaxel in Advanced Nonsquamous Nonâ€Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639. | 25.5 | 7,770 |
| 215 | Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. <i>Journal of Clinical Oncology</i> , 2015, 33, 2877-2884. | 17.1 | 183 |
| 216 | A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. <i>Science Translational Medicine</i> , 2015, 7, . | 13.1 | 438 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 217 | Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 4106-4111. | 17.1 | 263 |
| 218 | Preclinical oncology " reporting transparency needed. <i>Nature Reviews Clinical Oncology</i> , 2015, 13, 8-9. | 25.3 | 2 |
| 219 | Abstract 3752: Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer. <i>Cancer Research</i> , 2015, 75, 3752-3752. | 0.6 | 2 |
| 220 | Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies. , 2015, , . | | 0 |
| 221 | Abstract 610: Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing. , 2015, , . | | 0 |
| 222 | Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, . | 7.7 | 87 |
| 223 | Combining the pan"aurora kinase inhibitor <scp>AMG</scp> 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. <i>Cancer Medicine</i> , 2014, 3, 1322-1335. | 2.8 | 25 |
| 224 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998. | 13.7 | 1,376 |
| 225 | Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1669-1674. | 1.1 | 108 |
| 226 | RET Mutations in Neuroendocrine Tumors: Including Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1240-1242. | 1.1 | 12 |
| 227 | A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non"Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1031-1035. | 1.1 | 48 |
| 228 | A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non"Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277. | 1.1 | 31 |
| 229 | Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer. <i>American Journal of Medicine</i> , 2014, 127, 443-449. | 2.1 | 51 |
| 230 | Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 2846-2856. | 0.6 | 48 |
| 231 | SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. <i>Lung Cancer</i> , 2014, 85, 1-6. | 2.1 | 27 |
| 232 | Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, 414-418. | 1.1 | 33 |
| 233 | Abstract A12: Screening for TWIST1 inhibitors as a novel therapy for oncogene-driven lung cancer.. <i>Clinical Cancer Research</i> , 2014, 20, A12-A12. | 6.4 | 1 |
| 234 | Abstract IA03: Genomic and epigenomic targets in small cell lung cancer.. <i>Clinical Cancer Research</i> , 2014, 20, IA03-IA03. | 6.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 235 | Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer. , 2014, , . | | 0 |
| 236 | Abstract 3405: E12 and E47 are essential for TWIST1 dependent suppression of oncogene-induced senescence in NSCLC. , 2014, , . | | 0 |
| 237 | Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. <i>Molecular Cancer</i> , 2013, 12, . | 29.8 | 38 |
| 238 | Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 2584-2591. | 6.4 | 123 |
| 239 | Hedgehog Pathway Inhibition Radiosensitizes Non-Small Cell Lung Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 143-149. | 0.7 | 36 |
| 240 | The future of epigenetic therapy in solid tumours—lessons from the past. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 256-266. | 25.3 | 288 |
| 241 | Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothed Antagonists. <i>Cancer Cell</i> , 2013, 23, 23-34. | 33.4 | 289 |
| 242 | Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1273-1285. | 3.2 | 58 |
| 243 | Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 619-623. | 1.1 | 122 |
| 244 | The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis. <i>Molecular Cancer Research</i> , 2013, 11, 1387-1400. | 2.9 | 61 |
| 245 | Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1059-1065. | 5.1 | 105 |
| 246 | ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1131-1139. | 1.7 | 29 |
| 247 | Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 2766-2774. | 6.4 | 143 |
| 248 | Poly(β -amino ester) Nanoparticle Delivery of <i>TP53</i> Has Activity against Small Cell Lung Cancer <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 405-415. | 1.7 | 41 |
| 249 | Inhibition of <i>TWIST1</i> Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 329-338. | 2.9 | 50 |
| 250 | Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, e41-e42. | 1.1 | 84 |
| 251 | Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 78-98. | 16.1 | 310 |
| 252 | Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy.. , 2013, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 253 | Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e295-e300. | 5.1 | 8 |
| 254 | Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget, 2013, 4, 2067-2079. | 1.7 | 321 |
| 255 | Abstract B45: The Twist box domain is required for Twist1-induced metastasis of prostate cancer cells. , 2013, , . | | 0 |
| 256 | Abstract 5644: Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to vismodegib.. , 2013, , . | | 0 |
| 257 | Abstract 5675: Optimization of a Seneca Valley Virus (SVV) 3C protease substrate for virus-directed enzyme prodrug therapy.. , 2013, , . | | 0 |
| 258 | Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e295-e300. | 5.1 | 3 |
| 259 | Mobile Genetic Element Activation and Genotoxic Cancer Therapy. Molecular Diagnosis and Therapy, 2012, 2, 25-35. | 1.1 | 13 |
| 260 | Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine, 2012, 366, 2171-2179. | 25.5 | 1,160 |
| 261 | Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis. PLoS Genetics, 2012, 8, e1002650. | 3.3 | 79 |
| 262 | Vismodegib. Clinical Cancer Research, 2012, 18, 3218-3222. | 6.4 | 80 |
| 263 | Therapeutic potential of Hedgehog signaling inhibitors in cancer: rationale and clinical data. Clinical Investigation, 2012, 2, 371-385. | 0.4 | 1 |
| 264 | Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. Journal of General Virology, 2012, 93, 2606-2613. | 3.5 | 24 |
| 265 | Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived. Current Problems in Cancer, 2012, 36, 156-173. | 2.0 | 6 |
| 266 | Crizotinib in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2012, 13, 1195-1201. | 2.3 | 79 |
| 267 | Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics, 2012, 44, 1111-1116. | 16.3 | 852 |
| 268 | A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothed Antagonists. Molecular Cancer Therapeutics, 2012, 11, 165-173. | 1.7 | 71 |
| 269 | Cigarette smoking and lung cancerâ€™relative risk estimates for the major histological types from a pooled analysis of caseâ€™control studies. International Journal of Cancer, 2012, 131, 1210-1219. | 4.5 | 390 |
| 270 | Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 3163-3169. | 6.4 | 447 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 271 | Abstract 1802: IGF-1R inhibition as a novel therapeutic strategy for small cell lung cancer. , 2012, , . | | 0 |
| 272 | Abstract 2954: TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer. , 2012, , . | | 0 |
| 273 | Abstract 2049: Preclinical profile of AMG900 in combination with HDACIs in prostate cancer. , 2012, , . | | 0 |
| 274 | A phase II study of obatoclox mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 481-485. | 2.1 | 82 |
| 275 | Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 909-916. | 17.1 | 486 |
| 276 | Itraconazole Side Chain Analogues: Structure-Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7363-7374. | 6.9 | 37 |
| 277 | A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1757-1760. | 1.1 | 136 |
| 278 | DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. <i>Nature</i> , 2011, 471, 325-330. | 40.1 | 521 |
| 279 | Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 2502-2511. | 6.4 | 468 |
| 280 | Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1075-1082. | 17.1 | 42 |
| 281 | Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. <i>Clinical Cancer Research</i> , 2011, 17, 2512-2520. | 6.4 | 101 |
| 282 | Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features. <i>Clinical Cancer Research</i> , 2011, 17, 888-895. | 6.4 | 124 |
| 283 | Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. <i>Cancer Biology and Therapy</i> , 2011, 12, 617-628. | 4.3 | 25 |
| 284 | Notch Signaling Contributes to Lung Cancer Clonogenic Capacity <i>In Vitro</i> but May Be Circumvented in Tumorigenesis <i>In Vivo</i> . <i>Molecular Cancer Research</i> , 2011, 9, 1746-1754. | 2.9 | 36 |
| 285 | Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2011, 71, 6764-6772. | 0.6 | 134 |
| 286 | Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 598-607. | 26.4 | 571 |
| 287 | Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs. <i>Cancer Research</i> , 2011, 71, 2557-2557. | 0.6 | 2 |
| 288 | Abstract 5209: The roles of Notch signaling in the development of non-small cell lung cancer. , 2011, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 289 | Abstract 3271: Inhibition of angiogenesis and tumor growth by itraconazole in primary xenograft models of human non-small cell lung cancer. , 2011, , . | | 0 |
| 290 | Abstract 4292: Frequent detection of xenotropic murine leukemia virus (XMLV) strains including XMRV in human cultures established from mouse xenografts. , 2011, , . | | 0 |
| 291 | A phase I study of obatoclox mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2010, 66, 1079-1085. | 2.3 | 66 |
| 292 | Geographic Proximity and Racial Disparities in Cancer Clinical Trial Participation. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1343-1351. | 16.1 | 29 |
| 293 | The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center. Clinical Cancer Research, 2010, 16, 5997-6003. | 6.4 | 35 |
| 294 | Beyond the Scalpel: Targeting Hedgehog in Skin Cancer Prevention. Cancer Prevention Research, 2010, 3, 1-3. | 1.1 | 10 |
| 295 | Skin Deep and Deeper: Multiple Pathways in Basal Cell Carcinogenesis. Cancer Prevention Research, 2010, 3, 1213-1216. | 1.1 | 6 |
| 296 | Abstract 3738: Exploratory patient (pt) stratification markers associated with sensitivity to ABT-263 in small cell lung cancer (SCLC). , 2010, , . | | 0 |
| 297 | Determinants of Apoptotic Sensitivity to HSP90 Inhibition In Acute Myeloid Leukemia. Blood, 2010, 116, 2159-2159. | 1.0 | 0 |
| 298 | Cancer Stem Cells. Journal of Thoracic Oncology, 2009, 4, S1079-S1081. | 1.1 | 0 |
| 299 | Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies. Oncologist, 2009, 14, 119-124. | 3.6 | 19 |
| 300 | Lung Cancer in Never Smokers: A Call to Action: Fig. 1.. Clinical Cancer Research, 2009, 15, 5622-5625. | 6.4 | 33 |
| 301 | Upregulation of <i>MMP-2</i> by HMGA1 Promotes Transformation in Undifferentiated, Large-Cell Lung Cancer. Molecular Cancer Research, 2009, 7, 1803-1812. | 2.9 | 66 |
| 302 | Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clinical Cancer Research, 2009, 15, 5646-5661. | 6.4 | 129 |
| 303 | Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors. Clinical Cancer Research, 2009, 15, 5626-5645. | 6.4 | 422 |
| 304 | Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 264-270. | 17.1 | 45 |
| 305 | Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. New England Journal of Medicine, 2009, 361, 1164-1172. | 25.5 | 947 |
| 306 | Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. New England Journal of Medicine, 2009, 361, 1173-1178. | 25.5 | 862 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 307 | A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture <i>in vitro</i> . <i>Cancer Research</i> , 2009, 69, 3364-3373. | 0.6 | 387 |
| 308 | Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. <i>Blood</i> , 2009, 113, 2014-2021. | 1.0 | 172 |
| 309 | Randomized Phase II Study of Carboplatin and Etoposide With or Without the <i>bcl-2</i> Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103. <i>Journal of Clinical Oncology</i> , 2008, 26, 870-876. | 17.1 | 142 |
| 310 | Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. <i>Journal of Clinical Oncology</i> , 2008, 26, 1119-1127. | 17.1 | 180 |
| 311 | Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer. <i>Cancer Research</i> , 2008, 68, 2321-2328. | 0.6 | 177 |
| 312 | Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 59-67. | 1.1 | 6 |
| 313 | Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients. <i>Cancer Research</i> , 2008, 68, LB-138-LB-138. | 0.6 | 7 |
| 314 | SVF1 Regulates Cell Survival by Affecting Sphingolipid Metabolism in <i>Saccharomyces cerevisiae</i> . <i>Genetics</i> , 2007, 175, 65-76. | 4.2 | 18 |
| 315 | Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1623-1633. | 5.1 | 190 |
| 316 | A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 638-644. | 1.1 | 11 |
| 317 | Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. <i>Trends in Molecular Medicine</i> , 2007, 13, 150-157. | 10.0 | 25 |
| 318 | P2-175: Phase 1/2 trial of ABT-751 in combination with pemetrexed vs pemetrexed alone in subjects with advanced or metastatic non-small-cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S639. | 1.1 | 0 |
| 319 | DNA cleavage and Trp53 differentially affect SINE transcription. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 248-260. | 3.5 | 12 |
| 320 | Phase II study of PKC- δ antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 52, 173-180. | 2.1 | 30 |
| 321 | A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. <i>Lung Cancer</i> , 2006, 54, 69-77. | 2.1 | 35 |
| 322 | Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 245-251. | 1.1 | 22 |
| 323 | Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2006, 12, 1251-1259. | 6.4 | 73 |
| 324 | Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 64-72. | 2.9 | 142 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 325 | Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in <i>Saccharomyces cerevisiae</i> . <i>Yeast</i> , 2005, 22, 641-652. | 2.4 | 26 |
| 326 | Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate. <i>Molecular Cancer Research</i> , 2005, 3, 635-644. | 2.9 | 16 |
| 327 | Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1110-1117. | 17.1 | 150 |
| 328 | Delivery of a Liposomal c-ras-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 7244-7251. | 6.4 | 77 |
| 329 | Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan. <i>Journal of Clinical Oncology</i> , 2004, 22, 1382-1388. | 17.1 | 846 |
| 330 | Akt Stimulates Aerobic Glycolysis in Cancer Cells. <i>Cancer Research</i> , 2004, 64, 3892-3899. | 0.6 | 1,206 |
| 331 | Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. <i>Virology</i> , 2003, 313, 147-157. | 2.3 | 100 |
| 332 | Bcl-xL and Akt cooperate to promote leukemogenesis in vivo. <i>Oncogene</i> , 2003, 22, 688-698. | 6.6 | 30 |
| 333 | Human Alu element retrotransposition induced by genotoxic stress. <i>Nature Genetics</i> , 2003, 35, 219-220. | 16.3 | 103 |
| 334 | A phase II study of bryostatins and paclitaxel in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 191-196. | 2.1 | 38 |
| 335 | An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4546-4552. | 17.1 | 123 |
| 336 | Bcl-xL Complements <i>Saccharomyces cerevisiae</i> Genes That Facilitate the Switch from Glycolytic to Oxidative Metabolism. <i>Journal of Biological Chemistry</i> , 2002, 277, 44870-44876. | 2.3 | 58 |
| 337 | Phase I Study of Dose-Dense Alternating Doublets in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 3, 265-270. | 2.8 | 2 |
| 338 | Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. <i>Lung Cancer</i> , 2002, 38, 65-71. | 2.1 | 15 |
| 339 | Transcriptional activation of short interspersed elements by DNA-damaging agents. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 64-71. | 3.5 | 109 |
| 340 | Title is missing!. <i>Investigational New Drugs</i> , 2001, 19, 303-310. | 2.6 | 18 |
| 341 | Title is missing!. <i>Investigational New Drugs</i> , 2001, 19, 329-333. | 2.6 | 20 |
| 342 | A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 2, 128-132. | 2.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 343 | Signal transduction pathways that regulate cell survival and cell death. <i>Oncogene</i> , 1999, 17, 3207-3213. | 6.6 | 163 |
| 344 | Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. , 1999, 85, 164-170. | | 103 |
| 345 | APOPTOSIS AND DISEASE: Regulation and Clinical Relevance of Programmed Cell Death. <i>Annual Review of Medicine</i> , 1997, 48, 267-281. | 20.4 | 300 |
| 346 | Apoptotic signaling in lymphocytes. <i>Current Opinion in Hematology</i> , 1996, 3, 35-40. | 3.0 | 10 |